Is IDXX a good stock to buy?
IDEXX Laboratories, Inc. · end-of-day data as of Nov 13, 2026
- PT$741.67 +5.3%
- ConsensusBuy · 15
- MAs4 of 4
- MACD7.09
- Sector▲ +15.9%
- Earnings in80d
- P/E47.8x
- Support-2.8%
- Resistance+2.8%
- Off 52w high-8.5%
- Volume0.6x
- Bollingerupper half
- News0.00
- FCF yield+2.3%
- Trendsideways
- 52w range$501–$770
- ATR+3.5%
- Off ATH-8.5%
- P/E vs own+15.2%
- P/E vs sector+48.4%
- Insiders-$28.57M
- RSI72
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Idexx Laboratories a good stock to buy?
Idexx Laboratories is strong on 5 of the 5 questions about the business. The price is about usual: 47.8 times its earnings, near its 3-year median of 46.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage hard to copy
- Economics very profitable
- Execution delivers
- Fragility sturdy
- Price about usual
IDXX sales growth revenue growth
+9%a year, for the last 3 yearsIdexx Laboratories' sales grew 9% a year for 3 years, to $4.3B in fiscal 2025.
IDXX analysts' forecast revenue estimates
+10%the sales they expect next fiscal year, on the lastAnalysts expect Idexx Laboratories' sales to grow 10% to $4.75B in fiscal 2026 (11 analysts).
IDXX competitors
pretickt analysis+12%its sales in 12 months, on a year before
Idexx Laboratories' sales grew 12% in the 12 months to Sep 30, 2026, faster than IQVIA (+9%) and Agilent (+9%), slower than Waters (+81%) and Natera (+37%).
IDXX sales by business revenue by segment
59%of its sales from ProductProduct brought Idexx Laboratories 59% of its sales in fiscal 2025; Service 41%.
IDXX return on capital ROIC
pretickt analysis74%earned before tax on the money invested in itIdexx Laboratories earned 74% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Agilent 17%, IQVIA 11%, Waters 2% and Natera -26%.
IDXX margin on each sale gross margin
63%left after making the productIdexx Laboratories kept 63% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 52%.
IDXX margin after costs profit margin
32%of sales left after running the businessIdexx Laboratories' operating margin was 32% in the 12 months to Sep 30, 2026, against 27% in fiscal 2022.
IDXX cash generated free cash flow
$1.3Bcash left after investing, last 12 monthsIdexx Laboratories generated $1.3B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.
IDXX earnings vs estimates
8 of 8quarters above the analysts' estimateIdexx Laboratories beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 2, 2026.
IDXX insider selling
-$58.43Msold, net, by its executives in 12 monthsIdexx Laboratories' executives and directors sold a net $58.43M of shares in the 12 months to Nov 13, 2026; none bought.
IDXX number of employees
0%about as many people as a year beforeIdexx Laboratories had 11,000 employees at the end of fiscal 2025, about as many as a year before.
IDXX CEO pay
$14.58Mfor fiscal 2025, 74% of it in stock and optionsIdexx Laboratories paid its CEO $14.58M for fiscal 2025, 74% of it in stock and options.
IDXX financial health Altman Z-score
23.6Altman Z-score, safe above 3Idexx Laboratories' Altman Z-score is 23.6 (Nov 13, 2026), above 3, where the safe zone starts.
IDXX quality checks Piotroski score
9 of 9checks passedIdexx Laboratories passes all 9 Piotroski checks in the 12 months to Sep 30, 2026.
IDXX biggest customers
under 10%of sales from any one customerNo customer made 10% of Idexx Laboratories' sales in fiscal 2025.
IDXX in past recessions
pretickt analysis+1%its sales in the worst oneIdexx Laboratories' sales grew through each of the last 2 US recessions (2008–09 and 2020).
IDXX price vs profit P/E ratio
47.8×a year's earningsIdexx Laboratories' P/E ratio is 47.8 (Nov 13, 2026), near its 3-year median of 46.5.
IDXX price vs competitors
pretickt analysis47.8×a year's earnings, against its competitorsInvestors pay 47.8 times Idexx Laboratories' earnings (Nov 13, 2026), more than for Agilent (34.2) and IQVIA (32.2), less than for Waters (197.5).
IDXX analysts' target price target
+5%to their average targetAnalysts' average price target for Idexx Laboratories is $742, 5% above the Nov 13, 2026 close of $704.23.
IDXX growth priced in fair value
pretickt analysis+17%a year, for ten years, to be worth the priceAt $704.23 a share, Idexx Laboratories' free cash flow must grow about 17% a year for ten years to be worth the price (Nov 13, 2026).
What is Idexx Laboratories' P/E ratio?
Idexx Laboratories' P/E ratio is 47.8 (Nov 13, 2026), near its 3-year median of 46.5. Investors pay 47.8 times Idexx Laboratories' earnings (Nov 13, 2026), more than for Agilent (34.2) and IQVIA (32.2), less than for Waters (197.5).
Who are Idexx Laboratories' biggest competitors?
pretickt compares Idexx Laboratories with Agilent, Natera, Waters and IQVIA. Idexx Laboratories' sales grew 12% in the 12 months to Sep 30, 2026, faster than IQVIA (+9%) and Agilent (+9%), slower than Waters (+81%) and Natera (+37%).
Is Idexx Laboratories profitable?
Idexx Laboratories' operating margin was 32% in the 12 months to Sep 30, 2026, against 27% in fiscal 2022. Idexx Laboratories generated $1.3B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.
Are insiders selling Idexx Laboratories stock?
Idexx Laboratories' executives and directors sold a net $58.43M of shares in the 12 months to Nov 13, 2026; none bought.
How does Idexx Laboratories make money?
Product brought Idexx Laboratories 59% of its sales in fiscal 2025; Service 41%.
How many employees does Idexx Laboratories have?
Idexx Laboratories had 11,000 employees at the end of fiscal 2025, about as many as a year before.
Who are Idexx Laboratories' biggest customers?
No customer made 10% of Idexx Laboratories' sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.